EnglishFrenchGermanItalianSpanish

NeuMoDx™ Molecular And Sentinel Diagnostics Form A Partnership

Ann Arbor, MI USA and Milan, Italy (November 25, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on developing testing solutions for hospital and commercial reference laboratory customers, and Sentinel Diagnostics, a leading company engaged in the development and production of diagnostic kits for Clinical Chemistry, Immunochemistry and Molecular Biology, announced today their partnership to develop multiple diagnostic assays for the NeuMoDx™ 96 and 288 Molecular Systems.

NeuMoDx™ Molecular offers solutions that integrate the entire molecular diagnostic process – from extraction to detection or ‘sample to result’ – with the first result available in approximately one hour. These innovative analyzers provide operators with the ability to load up to 288 patient samples in a continuous, random-access workflow resulting in on-demand, high throughput sample processing with a true operator walkaway window of up to eight hours.

“Sentinel Diagnostics is a leader in developing innovative tests to meet the diagnostic testing needs of the clinical diagnostics laboratory and we are excited to partner with them as we continue to expand the test menu on our fully automated continuous random-access NeuMoDx™ Molecular systems.” said Jeff Williams, Chairman and CEO of NeuMoDx™ .

Sentinel Diagnostics has more than 35 years of experience in the development and production of IVD products. In Molecular Diagnostics, Sentinel developed STAT-NAT®, a proprietary technology able to stabilize the activity of PCR Mix, allowing room temperature transport and storage, performance improvement and long shelf life. STAT-NAT® can be customized for all NAT systems, from POC to central laboratory.

Sentinel’s real-time PCR assays will be adapted to the NeuMoDx™ 96 and 288 Molecular Systems and will incorporate the STAT-NAT® technology, which will be specifically optimized for the NeuMoDx™ Molecular systems. The result of this collaboration will be a broad portfolio of molecular diagnostic assays, providing a wide variety of clinical applications. The new test menu pipeline for the NeuMoDX™ Molecular systems will include assays to detect and monitor post-transplant infections, parasitic and hospital acquired infections, respiratory infections and for pharmacogenetics applications.

“Today, laboratories worldwide need to increase efficiency and throughput, while continuing to provide high quality results” said Ugo De Luca, CEO at Sentinel Diagnostics. “Vast experience in IVD development / manufacturing enabled Sentinel to develop STAT-NAT® patented technology, and produce lyophilized ready-to-use molecular tests, with high-sensitivity and specificity. In addition, with room temperature transport and storage, STAT-NAT® assays are eco-friendly – saving energy and reducing CO2 emissions. The partnership with NeuMoDx™ Molecular Systems is a win-win for both companies and benefits patients and diagnostic labs worldwide”.

About NeuMoDx™
NeuMoDx™ Molecular designs and develops revolutionary molecular diagnostic solutions for hospital and clinical reference laboratories. Our patented, ‘sample-to-result’ platform offers market-leading ease of use, true continuous random-access, and rapid turnaround time while achieving optimal operational and clinical performance for our customers and the patients they serve. For more information visit www.neumodx.com.

About Sentinel Diagnostics (Sentinel CH. S.p.A.)
Sentinel Diagnostics (Sentinel CH. SpA) is an Italian company based in Milan focused on the development and production of In Vitro Diagnostics for the most advanced Clinical Chemistry, Immunochemistry and Molecular Diagnostics platforms. Besides the wide product portfolio in Clinical Chemistry, the FOB Gold® line is Sentinel’s complete solution for colorectal cancer screening, which includes patented sampling devices and analytical systems. In the field of Molecular Biology, the STAT-NAT® portfolio is the company’s answer to the market need for easy, ready to use and eco-friendly Molecular Diagnostics, high in quality and sensitivity. For more information, visit www.sentineldiagnostics.com.

Contact:
NeuMoDx™ Molecular, Inc.
Daniel Harma
Chief Commercial Officer
dharma@neumodx.com

Sentinel Diagnostics (Sentinel CH. S.p.A.)
Mario Fangareggi
Head of Marketing
mariofangareggi@sentinel.it

Coronavirus Assay Information

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, has developed a SARS-CoV-2 Assay for use on the high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular Systems.

To learn more about SARS-CoV-2 testing, click here.
To order, click here.